Jimmy Gonzalez

Dr. Jimmy Gonzalez


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
TBTeresa Brown
Teresa Brown
JGJimmy Gonzalez
Jimmy Gonzalez
CMCatherine Monteleone
Catherine Monteleone

30 May 2024 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
JGJimmy Gonzalez
Jimmy Gonzalez
CDChintan V. Dave
Chintan V. Dave
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended for treatment of heart failure (HF), regardless of type 2 diabetes (T2DM) status. However, limited data exist on SGLT2i prescribing in HF patients without T2DM or across HF subtypes. Methods: This was a serial, cross-sectional study of US MarketScan commercial and Medicare claims (2013–2021). Prevalence of SGLT2i was calculated by calendar year among HFrEF and HFpEF patients and stratified by T2DM status. Results: Among 218,066 HFrEF patients [mean (SD): 54.9 (8.92) years; 66.4% male], the prevalence of SGLT2i use increased from 0.3 to 18.6%, while among 150,437 HFpEF patients [56.5 (7.77) years; 47.6% male], it rose from 0.5 to 9.9%. These increases were driven by the subgroup with comorbid T2DM. SGLT2i prevalence use ratios among patients with T2DM compared to those without decreased from > 100 in 2018 to 3.8 in 2021 among HFrEF patients, and from 83.1 in 2018 to 17.5 in 2021, coinciding with the publication of landmark trials and corresponding changes in clinical guidelines. Conclusions: SGLT2i use rose rapidly following changes in guidelines but remained low among those without T2DM. By the end of the study, approximately 1 in 3 HFrEF and 1 in 5 HFpEF patients with T2DM were using an SGLT2i, compared to only 1 in 11 HFrEF and 1 in 85 HFpEF patients without T2DM. Future work identifying barriers with the uptake of GDMT, including SGLT2i, among HF patients is needed.

1 January 2021 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
JGJimmy Gonzalez
Jimmy Gonzalez
LBLuigi Brunetti
Luigi Brunetti

24 April 2022 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
JGJimmy Gonzalez
Jimmy Gonzalez
VUVandan D. Upadhyaya
Vandan D. Upadhyaya
ZMZachary T. Manna
Zachary T. Manna
ASAditya R. Sharma
Aditya R. Sharma
JCJason Christopher
Jason Christopher
SSShuvendu Sen
Shuvendu Sen
Benzodiazepines are commonly used medications which are clinically useful towards the treatment of alcohol withdrawal, seizures, anxiety disorders, among other indications. Benzodiazepine use is also known to cause the rare phenomenon of paradoxical excitation whose mechanism has many postulated theories. We report this rare presentation of paradoxical excitation with the use of lorazepam in a 50-year-old male being treated for alcohol withdrawal. We also review the underlying pathophysiology, pharmacology, and current literature as it relates to this excitation. An inability to recognize this adverse effect and to appropriately withhold the agent may adversely affect a patient’s course of treatment in the inpatient setting.

1 July 2019 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
JGJimmy Gonzalez
Jimmy Gonzalez
SBSamantha Bryant
Samantha Bryant
MHMichael Hogan
Michael Hogan
SBSandra Bai
Sandra Bai
LFLesley Fierro
Lesley Fierro
EHEvelyn R. Hermes-DeSantis
Evelyn R. Hermes-DeSantis

5 November 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
THThomas Hong
Thomas Hong
JGJimmy Gonzalez
Jimmy Gonzalez
RNRonald Nahass
Ronald Nahass
Luigi BrunettiLuigi Brunetti
Luigi Brunetti
Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused significant health and economic havoc around the globe. One of the early agents targeted for repurposing to treat and prevent COVID-19 was hydroxychloroquine (HCQ). In this systematic review and meta-analysis, HCQ is evaluated for its potential role in decreasing mortality in hospitalized patients with COVID-19. We searched PubMed, Web of Science, and medRxiv databases using combinations of the terms “COVID-19”, “SARS-CoV-2”, “coronavirus”, “hydroxychloroquine”, and “mortality”. Articles were selected for further review based on the content of their abstracts. Studies were excluded if they were of poor methodological quality, were not based in the inpatient setting, or did not have available data to assess the primary outcome of death between patients treated with HCQ versus standard of care. Once the final dataset was compiled, a meta-analysis using the random-effects model was performed. Our search identified 14 studies involving 24,780 patients of whom 12,707 patients were on HCQ alone or in combination with other adjuvant therapies. HCQ alone or in combination with other drugs did not significantly decrease mortality in hospitalized patients with COVID-19 (odds ratio [OR], 0.95; 95% CI, 0.72–1.26; p = 0.732; I2 = 91.05). Similar findings were observed in all subgroup analyses. HCQ did not significantly impact mortality in hospitalized patients with COVID-19. Additional well-designed studies are essential due to the heterogeneity in available studies.